Novo Nordisk predicts period of "different" growth when semaglutide patents expire

The pharmaceutical company's growth profile will change when patents concerning the GLP-1 molecule semaglutide run out, says CEO at Novo Nordisk Lars Fruergaard Jørgensen.
Photo: Stine Bidstrup/ERH
Photo: Stine Bidstrup/ERH
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

When patents related to Novo Nordisk's bestselling GLP-1 molecule, semaglutide, expire, it might affect the company's growth, CEO at Novo Nordisk Lars Fruergaard Jørgensen tells Danish business daily Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading